NERVGEN PHARMA CORP. Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019
NERVGEN PHARMA CORP. (NGEN) had Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 of 2.31 CAD/shares as of 2025-12-31, per its 40-F filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019 · last filed 2026-03-31
- 2025-12-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 2.31 CAD/shares.
- 2024-12-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 2.05 CAD/shares.
- 2023-12-31: Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 1.91 CAD/shares.
| Period end | Weighted Average Exercise Price Of Share Options Outstanding In Share-based Payment Arrangement2019 |
|---|---|
| 2025-12-31 | 2.31 CAD/shares 40-F · filed 2026-03-31 |
| 2024-12-31 | 2.05 CAD/shares 40-F · filed 2026-03-31 |
| 2023-12-31 | 1.91 CAD/shares 40-F · filed 2026-03-31 |